The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Onset of neutropenia as an indicator of treatment response in the randomized phase II of TAS-102 vs placebo in Japanese patients with metastatic colorectal cancer (Study J003-10040030).
 
Tomohiro Nishina
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda
 
Takayuki Yoshino
Research Funding - Sumitomo Dainippon
 
Eiji Shinozaki
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Bristol-Myers Squibb Japan (Inst)
 
Yoshito Komatsu
Honoraria - Bayer; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MSD; Novartis; Pfizer; Taiho Pharmaceutical; Takeda; Yakult Honsha
Speakers' Bureau - Bayer; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Novartis; Pfizer; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Bayer; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MSD; Novartis; Pfizer; Taiho Pharmaceutical; Takeda
 
Hideo Baba
Speakers' Bureau - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical (Inst)
 
Akihito Tsuji
Honoraria - Chugai Pharma; Daiichi Sankyo; Merck Serono; Taiho Pharmaceutical
 
Kensei Yamaguchi
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Merck Serono; Takeda
 
Kei Muro
Honoraria - Chugai Pharma; Takeda; Yakult Honsha
Consulting or Advisory Role - Takeda
 
Naotoshi Sugimoto
No Relationships to Disclose
 
Yasushi Tsuji
No Relationships to Disclose
 
Toshikazu Moriwaki
Honoraria - Chugai Pharma; Merck; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Boehringer Ingelheim (Inst); MSD (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Taito Esaki
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Daiichi Sankyo; Lilly Japan; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
 
Chikuma Hamada
Consulting or Advisory Role - Taiho Pharmaceutical
 
Takanori Tanase
Employment - Taiho Pharmaceutical
Stock and Other Ownership Interests - Otsuka
 
Atsushi Ohtsu
Employment - Celgene (I)
Research Funding - Bristol-Myers Squibb